Since its introduction in the 1970s, Paclitaxel has been used as an effective anticancer
agent against lung, breast, ovarian, leukopenia and liver cancer. But, Paclitaxel-induced
peripheral neuropathy is the major dose-limiting side effect of paclitaxel.Paclitaxel induced
peripheral neuropathy most commonly presents as
3. Tingling ("pins and needles" feeling) or electric/shock-like pain,
6. Increased sensitivity to cold or heat These symptoms are classically seen symmetrically
in the distal extremities (glove and stocking distribution).
Most adverse effects associated with chemotherapy are ameliorated after cessation of the
therapy, but CIPN may persist in the longterm, with 30 % patients having CIPN related
symptoms beyond 6 months after completion of chemotherapy7.Understanding the epidemiology of
neuropathic pain in breast cancer patients has high clinical and public health significance.